

**ANTISOMA PLC
SHAREHOLDER APPROVAL FOR COMPLETION OF PLACING AND OPEN OFFER**

18 December 2003

Antisoma plc ("Antisoma" or the "Company") announces that at an Extraordinary General Meeting held earlier today the Resolutions proposed and required to implement a Placing and Open Offer to raise £15.2 million were duly passed.

On 25 November 2003, the Company announced a Placing and Open Offer of 38,010,941 New Shares at 40 pence per share to raise approximately £15.2 million (approximately £14.0 million net of expenses). 8,171,103 New Shares were placed firm with institutional investors and 29,839,838 New Shares were placed with institutional investors subject to clawback to satisfy valid applications by Qualifying Shareholders of the Company under the Open Offer.

The Open Offer to Qualifying Shareholders closed at 3.00 pm on 17 December 2003. Applications were received in respect of 3,676,779 New Shares, including the 159,790 New Shares the Directors of Antisoma agreed to take up under the Open Offer. These shares, amounting in total to 12.3% of those available under the Open Offer, were therefore clawed back from the allocations of institutional investors. The remaining 26,163,059 New Shares and the 8,171,103 New Shares that were placed firm (constituting a total of 34,334,162 New Shares), will be taken up by new and existing institutional investors pursuant to the Placing by Nomura International plc.

Application has been made to the UK Listing Authority for the New Shares to be admitted to the Official List and to the London Stock Exchange for admission to trading. It is expected that dealings in the New Shares will commence at 8.00 am on 19 December 2003, following their admission to the Official List of the UK Listing Authority and to trading on the market for listed securities of the London Stock Exchange. CREST stock accounts are expected to be credited on 19 December 2003 and definitive share certificates in respect of New Shares are expected to be posted, where applicable, by 29 December 2003.

Commenting, Glyn Edwards, CEO of Antisoma, said, "We're delighted to have successfully completed a £15.2 million fundraising, enabling us to make additional investment in the further development of our cancer drug pipeline."

Enquiries:

Antisoma plc

Glyn Edwards, Chief Executive Officer
Raymond Spencer, Chief Financial Officer

Tel: +44 (0)20 8799 8200

Nomura International plc

Dave Rasouly
John Milad

Tel: +44 (0)20 7521 2000

Financial Dynamics

Ben Atwell
Sarah MacLeod

Tel: +44 (0)20 7831 3113

Terms defined in the prospectus issued by Antisoma dated 25 November 2003 shall, unless the context admits otherwise, have the same meaning in this announcement.

Nomura International plc is acting exclusively for Antisoma in relation to the Placing and Open Offer and is not advising any other person or treating any other person as its client in relation thereto, and will not be responsible to any person other than Antisoma for providing the protections afforded to its clients nor for providing advice in relation to the Placing, Open Offer or any other matter referred to in this announcement.

This announcement does not constitute an offer to sell, or the solicitation of an offer to subscribe for, the New Shares in any jurisdiction in which such offer or solicitation is unlawful. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 (as amended), under the securities laws of any state of the United States or under the applicable securities laws of Canada, Australia, the Republic of Ireland or Japan. Accordingly, unless an exemption under any applicable law is available, the New Shares may not be offered, sold, transferred, taken up or delivered, directly or indirectly, in the United States of America, Australia, Canada, the Republic of Ireland, or Japan or any other country outside the United Kingdom where such distribution may otherwise lead to a breach of any law or regulatory requirement.

About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. The Company fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma forms partnerships with pharmaceutical companies to bring its products to market. In November 2002, Antisoma formed a broad strategic alliance with Roche to develop and commercialise products from Antisoma's pipeline. Please visit www.antisoma.com for further information about Antisoma.